Anti-™EM268 monoclonal antibody
Pre-made anti-™EM268 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to ™EM268/™EM268 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
Product information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP2772-Ab-1/ GM-Tg-hg-IP2772-Ab-2 | Anti-Human ™EM268 monoclonal antibody | Human |
| GM-Tg-rg-IP2772-Ab-1/ GM-Tg-rg-IP2772-Ab-2 | Anti-Rat ™EM268 monoclonal antibody | Rat |
| GM-Tg-mg-IP2772-Ab-1/ GM-Tg-mg-IP2772-Ab-2 | Anti-Mouse ™EM268 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP2772-Ab-1/ GM-Tg-cynog-IP2772-Ab-2 | Anti-Cynomolgus/ Rhesus macaque ™EM268 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP2772-Ab-1/ GM-Tg-felg-IP2772-Ab-2 | Anti-Feline ™EM268 monoclonal antibody | Feline |
| GM-Tg-cang-IP2772-Ab-1/ GM-Tg-cang-IP2772-Ab-2 | Anti-Canine ™EM268 monoclonal antibody | Canine |
| GM-Tg-bovg-IP2772-Ab-1/ GM-Tg-bovg-IP2772-Ab-2 | Anti-Bovine ™EM268 monoclonal antibody | Bovine |
| GM-Tg-equg-IP2772-Ab-1/ GM-Tg-equg-IP2772-Ab-2 | Anti-Equine ™EM268 monoclonal antibody | Equine |
Size: 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP2772-Ab-1/ GM-Tg-hg-IP2772-Ab-2; GM-Tg-rg-IP2772-Ab-1/ GM-Tg-rg-IP2772-Ab-2; GM-Tg-mg-IP2772-Ab-1/ GM-Tg-mg-IP2772-Ab-2; GM-Tg-cynog-IP2772-Ab-1/ GM-Tg-cynog-IP2772-Ab-2; GM-Tg-felg-IP2772-Ab-1/ GM-Tg-felg-IP2772-Ab-2; GM-Tg-cang-IP2772-Ab-1/ GM-Tg-cang-IP2772-Ab-2; GM-Tg-bovg-IP2772-Ab-1/ GM-Tg-bovg-IP2772-Ab-2; GM-Tg-equg-IP2772-Ab-1/ GM-Tg-equg-IP2772-Ab-2 |
| Products Name | Anti-™EM268 monoclonal antibody |
| Format | mab |
| Target Name | ™EM268 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-™EM268 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP2772-Ag-1 | Recombinant multi-species ™268/ ™EM268/ C9orf91 protein |
| ORF Viral Vector | pGMLPm002299 | mouse Tmem268 Lentivirus plasmid |
| ORF Viral Vector | vGMLPm002299 | mouse Tmem268 Lentivirus particle |
Target information
| Target ID | GM-IP2772 |
| Target Name | ™EM268 |
| Gene ID | 203197,230279,298104,703539,612595,101099252,535122,100049971 |
| Gene Symbol and Synonyms | 6330416G13Rik,bM230C2.2,C11H9orf91,C8H9orf91,C9orf91,RGD1304595,™EM268 |
| Uniprot Accession | Q5VZI3,Q5EA48 |
| Uniprot Entry Name | ™268_HUMAN,™268_BOVIN |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | N/A |
| Gene Ensembl | ENSG00000157693 |
| Target Classification | N/A |
The target: ™EM268, gene name: ™EM268, also named as C9orf91. Predicted to be integral component of membrane. [provided by Alliance of Genome Resources, Apr 2022].
About Gmab


GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.

